Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review

Central nervous system (CNS) ‐relapsed mantle cell lymphoma (MCL) is a rare, aggressive non‐Hodgkin lymphoma without a standard treatment. Ibrutinib has shown promising results for inducing remission in other non‐Hodgkin lymphomas and may be considered as successful treatment for CNS‐relapsed MCL in the future as well. AbstractCentral nervous system (CNS) ‐relapsed mantle cell lymphoma (MCL) is a rare, aggressive non‐Hodgkin lymphoma without a standard treatment. Ibrutinib has shown promising results for inducing remission in other non‐Hodgkin lymphomas and may be considered as successful treatment for CNS‐relapsed MCL in the future as well.
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research